• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

One Drug Stopped Progression Of Many Types Of Cancer In Small Trial

March 25, 2023 by Deborah Bloomfield

ATX-101 is an experimental drug designed to kill cells of all types of cancers, while leaving healthy cells untouched. A trial of cancer patients for whom all existing treatments had failed was intended just to test ATX-101’s safety. For many of those participating it appears to have extended their lives, halting the progression of their disease for months or years.

If someone claims to have a “cure for cancer” you can usually safely assume it’s a scam. Cancer isn’t one disease. The wide variety of types have distinct causes, varying symptoms, and affect different parts of the body. We’ve made spectacular progress against some of these, very little against others. It doesn’t make much sense to think a single treatment will cure everything.

Advertisement

ATX-101 isn’t likely to represent a universal cancer cure, but the results of its Phase I trial, reported in a new study, suggest the dream might not be as ridiculous as previously thought. By targeting a feature common to cancer cells in different organs the drug may reveal a crucial point of vulnerability for all forms of the disease. If so, future drugs could attack this weak spot with ever greater precision.

“Cancer cells are more stressed than other cells. However, they don’t die but continue to grow even when they are damaged,” said Professor Marit Otterlei, of the Norwegian University of Science and Technology, in a statement. “Conventional cancer treatment with chemotherapy puts more stress on the cancer cells so that the cells eventually do die.” 

Unfortunately, chemotherapy also damages healthy cells, so there is only so much that can be given before the cure becomes worse than the disease. An increasing array of drugs target cancer cells in other ways, but only work on a single sort of cancer, or at best a few types.

Otterlei’s solution was to look for molecules that only affect cells that show cancer’s specific form of stress, and have no effect on others. ATX-101 is the first she has found that performs well enough in vitro and in animal studies to be tried in humans.

Advertisement

“ATX-101 can be used as the only treatment. It can stabilize the cancer as shown in the recently published studies, but the medicine can also help chemotherapy work even better so that you don’t have to have so much of it,” Otterlei said.

For the trial, 25 patients with a variety of cancers were given ATX-101 intravenously in one of four doses. Even at the highest dosage none of the patients found the treatment intolerable, and most reported only mild side-effects, such as itching around the site of the infusion.

Half the patients had received at least four different treatments prior to enrolment in the trial, and in almost all cases all had not worked or had stopped working. Twelve responded well enough over six weeks that they extended their participation. Eight of these experienced a substantial pause in the progression of the disease; for one, the cancer was no larger 29 months later. The sample size was far too small to determine if some forms of cancer are more susceptible than others.

Otterlei’s breakthrough was to discover a binding sequence, which she named APIM, that regulates stress in cells, binding to the PCNA coordinator molecule when pressures are high. It’s taken her 18 years from finding APIM to the two Phase 2 trials currently being conducted against sarcomas and ovarian cancer, respectively.

Advertisement

To do that Otterlei and colleagues needed to make an APIM-containing drug that binds to PCNA and prevents it from interacting with proteins, disrupting the cancerous cells to their destruction while apparently leaving healthy cells alone. ATX-101 can also re-sensitize cancer cells that have developed resistance to standard chemotherapies, restoring the effectiveness of treatments that were no longer working.

In the process of her cancer research Otterlei accidentally discovered a potential new class of antibiotics.

 The study is published in Oncogene (open access).

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Exclusive-China’s Miniso to double U.S. stores, add NY ‘flagship’ as pandemic slashes mall rents
  2. Indian food delivery giant Swiggy in talks to raise funds at over $10 billion valuation
  3. Soccer-Rashford receives honorary doctorate from University of Manchester
  4. Myth Or Magic: Duck Quacks Don’t Echo

Source Link: One Drug Stopped Progression Of Many Types Of Cancer In Small Trial

Filed Under: News

Primary Sidebar

  • Ever Seen A Giraffe Use An Inhaler? Now You Can, And It’s Incredibly Wholesome
  • Martian Mudstone Has Features That Might Be Biosignatures, New Brain Implant Can Decode Your Internal Monologue, And Much More This Week
  • Crocodiles Weren’t All Blood-Thirsty Killers, Some Evolved To Be Plant-Eating Vegetarians
  • Stratospheric Warming Event May Be Unfolding In The Southern Polar Vortex, Shaking Up Global Weather Systems
  • 15 Years Ago, Bees In Brooklyn Appeared Red After Snacking Where They Shouldn’t
  • Carnian Pluvial Event: It Rained For 2 Million Years — And It Changed Planet Earth Forever
  • There’s Volcanic Unrest At The Campi Flegrei Caldera – Here’s What We Know
  • The “Rumpelstiltskin Effect”: When Just Getting A Diagnosis Is Enough To Start The Healing
  • In 1962, A Boy Found A Radioactive Capsule And Brought It Inside His House — With Tragic Results
  • This Cute Creature Has One Of The Largest Genomes Of Any Mammal, With 114 Chromosomes
  • Little Air And Dramatic Evolutionary Changes Await Future Humans On Mars
  • “Black Hole Stars” Might Solve Unexplained JWST Discovery
  • Pretty In Purple: Why Do Some Otters Have Purple Teeth And Bones? It’s All Down To Their Spiky Diets
  • The World’s Largest Carnivoran Is A 3,600-Kilogram Giant That Weighs More Than Your Car
  • Devastating “Rogue Waves” Finally Have An Explanation
  • Meet The “Masked Seducer”, A Unique Bat With A Never-Before-Seen Courtship Display
  • Alaska’s Salmon River Is Turning Orange – And It’s A Stark Warning
  • Meet The Heaviest Jelly In The Seas, Weighing Over Twice As Much As A Grand Piano
  • For The First Time, We’ve Found Evidence Climate Change Is Attracting Invasive Species To Canadian Arctic
  • What Are Microfiber Cloths, And How Do They Clean So Well?
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version